Ebola as a case study for the patent landscape of medical countermeasures for emerging infectious diseases

Nature Biotechnology
Volume 39 Issue 7, July 2021
https://www.nature.com/nbt/volumes/39/issues/7

 

Patents | 13 July 2021
Ebola as a case study for the patent landscape of medical countermeasures for emerging infectious diseases
A survey of patenting activity can facilitate coordination of R&D activities to fight emerging infectious diseases.
Nasir Mohajel, Arash Arashkia

Transforming global health through equity-driven funding

Nature Medicine
Volume 27 Issue 7, July 2021
https://www.nature.com/nm/volumes/27/issues/7

 

Comment | 24 June 2021
Transforming global health through equity-driven funding
Black people living in Africa must be involved in setting the priorities for global health research, policies and programs that affect their daily lives, in order to move away from a funding culture that fosters colonialism, racism and white supremacy.
Jacob O. Olusanya, Olufunmilayo I. Ubogu, Bolajoko O. Olusanya

Equitable allocation of COVID-19 vaccines in the United States

Nature Medicine
Volume 27 Issue 7, July 2021
https://www.nature.com/nm/volumes/27/issues/7

 

Analysis | 18 May 2021
Equitable allocation of COVID-19 vaccines in the United States
An analysis of COVID-19 vaccine allocation frameworks in the United States across 64 Centers for Disease Control and Prevention jurisdictions reveals that, as of 31 March 2021, 37 jurisdictions had adopted disadvantage indices to reduce health disparities. The analysis also highlights the importance of vaccine prioritization based on health and place.
Harald Schmidt, Rebecca Weintraub, Angela A. Shen

Testing at scale during the COVID-19 pandemic

Nature Reviews Genetics
Volume 22 Issue 7, July 2021
https://www.nature.com/nrg/volumes/22/issues/7

 

Review Article | 04 May 2021
Testing at scale during the COVID-19 pandemic
Population-scale testing is an essential component of responses to the COVID-19 pandemic and is likely to become increasingly important in public health. Here, Mercer and Salit describe the roles of testing during the COVID-19 pandemic, including in genomic surveillance, contact tracing and environmental testing.
Tim R. Mercer, Marc Salit

COVID-19 vaccine success enables a bolder vision for mRNA cancer vaccines, says BioNTech CEO

Nature Reviews Drug Discovery
Volume 20 Issue 7, July 2021
https://www.nature.com/nrd/volumes/20/issues/7

 

An Audience With
COVID-19 vaccine success enables a bolder vision for mRNA cancer vaccines, says BioNTech CEO
Uğur Şahin, an oncologist and mRNA pioneer, discusses his firm’s development plans for cancer vaccines, mRNA-encoded proteins and more.
Asher Mullard

Averting Future Vaccine Injustice

New England Journal of Medicine
July 15, 2021 Vol. 385 No. 3
http://www.nejm.org/toc/nejm/medical-journal

 

Perspective
Averting Future Vaccine Injustice S. Moon, A. Alonso Ruiz, and M. Vieira
Both rapid innovation and equitable access to vaccines are necessary to protect the world from viral pandemics. Today, however, we face gross inequities in global access to Covid-19 vaccines. As high-income countries, such as the United States and European countries, have secured a majority of the world’s vaccine supply (more than twice the volumes needed to cover their populations1), many low-income countries have barely begun the immunization process. It will take political courage to end such vaccine injustice now and political vision to negotiate the binding international rules needed to avert similar inequities in the future…

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

New England Journal of Medicine
July 15, 2021 Vol. 385 No. 3
http://www.nejm.org/toc/nejm/medical-journal

 

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents R.W. Frenck, Jr., and Others
Conclusions
The BNT162b2 vaccine in 12-to-15-year-old recipients had a favorable safety profile, produced a greater immune response than in young adults, and was highly effective against Covid-19. (Funded by BioNTech and Pfizer; C4591001 ClinicalTrials.gov number, NCT04368728. opens in new tab.)

The Myanmar military coup: Propelling the 2030 milestones for neglected tropical diseases further out of reach

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 17 Jul 2021)

 

Viewpoints
The Myanmar military coup: Propelling the 2030 milestones for neglected tropical diseases further out of reach
Bethany Moos, Russell Roberts, Mo Aye
| published 15 Jul 2021 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0009532

Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2

PLoS One
http://www.plosone.org/
[Accessed 17 Jul 2021]

 

Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2
Madison Stoddard, Sharanya Sarkar, Lin Yuan, Ryan P. Nolan, Douglas E. White, Laura F. White, Natasha S. Hochberg, Arijit Chakravarty
Research Article | published 16 Jul 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0254734

The impact of vaccination to control COVID-19 burden in the United States: A simulation modeling approach

PLoS One
http://www.plosone.org/
[Accessed 17 Jul 2021]

 

The impact of vaccination to control COVID-19 burden in the United States: A simulation modeling approach
Oguzhan Alagoz, Ajay K. Sethi, Brian W. Patterson, Matthew Churpek, Ghalib Alhanaee, Elizabeth Scaria, Nasia Safdar
Research Article | published 14 Jul 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0254456

Beware explanations from AI in health care

Science
16 July 2021 Vol 373, Issue 6552
http://www.sciencemag.org/current.dtl

 

Policy Forum
Beware explanations from AI in health care
By Boris Babic, Sara Gerke, Theodoros Evgeniou, I. Glenn Cohen
Science16 Jul 2021 : 284-286 Restricted Access
The benefits of explainable artificial intelligence are not what they appear
Summary
Artificial intelligence and machine learning (AI/ML) algorithms are increasingly developed in health care for diagnosis and treatment of a variety of medical conditions (1). However, despite the technical prowess of such systems, their adoption has been challenging, and whether and how much they will actually improve health care remains to be seen. A central reason for this is that the effectiveness of AI/ML-based medical devices depends largely on the behavioral characteristics of its users, who, for example, are often vulnerable to well-documented biases or algorithmic aversion (2). Many stakeholders increasingly identify the so-called black-box nature of predictive algorithms as the core source of users’ skepticism, lack of trust, and slow uptake (3, 4). As a result, lawmakers have been moving in the direction of requiring the availability of explanations for black-box algorithmic decisions (5). Indeed, a near-consensus is emerging in favor of explainable AI/ML among academics, governments, and civil society groups. Many are drawn to this approach to harness the accuracy benefits of noninterpretable AI/ML such as deep learning or neural nets while also supporting transparency, trust, and adoption. We argue that this consensus, at least as applied to health care, both overstates the benefits and undercounts the drawbacks of requiring black-box algorithms to be explainable.

A systematic review and meta-analysis of effectiveness of decision aids for vaccination decision-making

Vaccine
Volume 39, Issue 28 Pages 3645-3784 (23 June 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/28

 

Review article Abstract only
A systematic review and meta-analysis of effectiveness of decision aids for vaccination decision-making
Cassandra Vujovich-Dunn, Jessica Kaufman, Catherine King, S. Rachel Skinner, … Julie Leask
Pages 3655-3665

A systematic review and meta-analysis of effectiveness of decision aids for vaccination decision-making

Vaccine
Volume 39, Issue 28 Pages 3645-3784 (23 June 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/28

 

Review article Abstract only
A systematic review and meta-analysis of effectiveness of decision aids for vaccination decision-making
Cassandra Vujovich-Dunn, Jessica Kaufman, Catherine King, S. Rachel Skinner, … Julie Leask
Pages 3655-3665

Human papillomavirus (HPV) vaccine uptake among a community-recruited sample of gay, bisexual, and other men who have sex with men in the three largest cities in Canada from 2017 to 2019

Vaccine
Volume 39, Issue 28 Pages 3645-3784 (23 June 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/28

 

Research article Open access
Human papillomavirus (HPV) vaccine uptake among a community-recruited sample of gay, bisexual, and other men who have sex with men in the three largest cities in Canada from 2017 to 2019
R. Grewal, S.L. Deeks, T.A. Hart, J. Cox, … A.N. Burchell
Pages 3756-3766

The impact of an educational forum intervention on East African mothers’ HPV vaccine-related knowledge, attitudes, and intentions to vaccinate their adolescent children

Vaccine
Volume 39, Issue 28 Pages 3645-3784 (23 June 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/28

 

Research article Abstract only
The impact of an educational forum intervention on East African mothers’ HPV vaccine-related knowledge, attitudes, and intentions to vaccinate their adolescent children
Huong Chu, Linda K. Ko, Anisa Ibrahim, Farah Bille Mohamed, … Rachel L. Winer
Pages 3767-3776

Using Household Surveys to Assess Missed Opportunities for Simultaneous Vaccination: Longitudinal Examples from Colombia and Nigeria

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines

 

Open Access Article
Using Household Surveys to Assess Missed Opportunities for Simultaneous Vaccination: Longitudinal Examples from Colombia and Nigeria
by Dale A. Rhoda, et al.
Vaccines 2021, 9(7), 795; https://doi.org/10.3390/vaccines9070795 (registering DOI) – 16 Jul 2021
Abstract
One important strategy to increase vaccination coverage is to minimize missed opportunities for vaccination. Missed opportunities for simultaneous vaccination (MOSV) occur when a child receives one or more vaccines but not all those for which they are eligible at a given visit. Household […]

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
The sheer volume of vaccine and pandemic-related coverage is extraordinary. We will strive to present the most substantive analysis and commentary we encounter.

 

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 17 Jul 2021
Family
We Could Have Changed the World
The upheaval of the pandemic was an opportunity to imagine a better society. Instead, we’re rushing back to “normal.”
By Ekemini Uwan

 

BBC
http://www.bbc.co.uk/
Accessed 17 Jul 2021
[No new, unique, relevant content]

 

The Economist
http://www.economist.com/
Accessed 17 Jul 2021
Lexington
The Republican anti-vax delusion
America’s vaccination programme is stalling. Populist conservatives are to blame
United States Jul 17th 2021 edition

The next catastrophe
A wave of covid-19 is engulfing Indonesia
The government’s response is too little, too late
Jul 17th 2021 edition

 

Financial Times
https://www.ft.com/
Coronavirus pandemic
Top US health official warns of ‘pandemic of the unvaccinated’
July 17, 2021

 

Forbes
https://www.forbes.com/
Accessed 17 Jul 2021
[No new, unique, relevant content]

 

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 17 Jul 2021
[No new, unique, relevant content]

 

Foreign Policy
http://foreignpolicy.com/
Accessed 17 Jul 2021
[No new, unique, relevant content]

 

New Yorker
http://www.newyorker.com/
Accessed 17 Jul 2021
Medical Dispatch
Treating the Unvaccinated
In Utah, and across the U.S., doctors are facing a wave of preventable COVID deaths—and trying to convince the hesitant that “it doesn’t have to be this way.”
By Dhruv Khullar
July 16, 2021

 

New York Times
http://www.nytimes.com/
Accessed 17 Jul 2021
Politics
How Republican Vaccine Opposition Got to This Point
In recent months, Republican skepticism of Covid vaccines and their rollout has grown louder: One recent poll found that 47 percent said they weren’t likely to get vaccinated.
By Lisa Lerer July 17, 2021

 

Washington Post
https://www.washingtonpost.com/
Accessed 17 Jul 2021
France: Thousands protest against vaccination, COVID passes
· Jul 17, 2021

Think Tanks et al

Think Tanks et al
 
 
Brookings
http://www.brookings.edu/
Accessed 17 Jul 2021
[No new digest content identified]
 
 
Center for Global Development [to 17 Jul 2021]
http://www.cgdev.org/page/press-center
Publication
What’s Next? Predicting The Frequency and Scale of Future Pandemics
Event
7/20/21
Amid a pandemic, it is difficult to consider preparing for the next one, especially when there is no certainty about its timing. COVID-19 is broadly viewed as being a “once in a lifetime” or “once in a century” pandemic; unfortunately, that is not accurate. But what is the actual return time to a future pandemic threat, and how can we ensure that the world is prepared next time?

World Leaders: It Is Time for New Global Funding to Keep the World Safer from Pandemics
July 15, 2021
This past weekend, the High-Level Independent Panel on Financing the Global Commons for Pandemic Preparedness and Response delivered a stark warning in its report to the G20 Finance Ministers and Central Bank Governors meeting in Venice: With the near certainty of an even more deadly and costly pandemic than COVID-19 occurring within the next decade, the clock is ticking to ramp up investments in international preparedness.
Amanda Glassman and Carolyn Reynolds
 
 
Chatham House [to 17 Jul 2021]
https://www.chathamhouse.org/
Accessed 17 Jul 2021
Research paper
Solidarity in response to the COVID-19 pandemic
Has the world worked together to tackle the coronavirus?
14 July 2021 ISBN: 978 1 78413 481 5
PDF: https://www.chathamhouse.org/sites/default/files/2021-07/2021-07-14-solidarity-response-covid-19-pandemic-rahman-shepherd-et-al_0.pdf
It has frequently been stated during the COVID-19 pandemic that ‘no one is safe until we are all safe’. This is most commonly talked of between nations, but, importantly, it also applies within countries.
Besides the elderly, the pandemic has disproportionately affected the disadvantaged, the poor, the vulnerable, minorities, migrants and other neglected and marginalized groups, in all societies. It has been prolonged by the failure in many countries to adequately support and protect these groups. Where solidarity has been weak, inequities have widened, and effective responses to the pandemic have been frustrated.
This research paper assesses how the global community has responded to calls for greater solidarity in tackling the COVID-19 pandemic, and presents the insights of key stakeholders and experts in global health governance, health security, and pandemic preparedness and response. The authors examine the state of solidarity at global, regional and national levels, and present case studies on COVAX and on the EU’s turbulent journey through solidarity.

 
 
CSIS
https://www.csis.org/
Accessed 17 Jul 2021
Critical Questions
Minding the Gap in Global Immunization Coverage
July 16, 2021 | By Katherine E. Bliss

 
 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
July 16, 2021 News Release
KFF/UNAIDS Analysis Finds That While Donor Government Spending on HIV Increased in 2020, Future Funding is Uncertain with COVID-19 Challenges
A new report from KFF (Kaiser Family Foundation) and The Joint United Nations Programme on HIV/AIDS (UNAIDS) finds that donor government disbursements to combat HIV in low- and middle-income countries increased by US$377 million in 2020, reaching US$8.2 billion in 2020 compared to US$7.8 billion in 2019. Donor government funding…

July 13, 2021 News Release
Vaccine Monitor: Some Who Were Hesitant to Get a Vaccine in January Say They Changed Their Mind Because of Family, Friends and Their Personal Doctors
A new KFF COVID-19 Vaccine Monitor report finds that people who were initially hesitant to get a vaccine in January but ultimately did so often say that family, friends and their personal doctors helped change their minds. The report features a second round of interviews with a nationally representative sample…

Vaccines and Global Health: The Week in Review :: 10 July 2021

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version A pdf of the current issue is available here: 

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

COVID

Milestones :: Perspectives :: Research

 

COVID

 

Editor’s Note:
As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive, If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me…we will review all suggestions and consider for inclusion in a subsequent edition: david.r.curry@ge2p2global.org

We are seeking access to modelling which engages scenarios and articulates imperatives around a pandemic end-game through at least a 2025 horizon. We assess that WHO must be conducting or contracting for such modeling – or should recognize an imperative to be doing so in its global health governance role. If we have missed such modeling in progress, we would be delighted to be advised of it and will include it in our coverage.

Secretary-General Calls for ‘Greatest Global Public Health Effort in History’ to Bridge Vaccine Gap as World Marks 4 Million Deaths from COVID-19 Pandemic

Milestones :: Perspectives :: Research

 

Secretary-General Calls for ‘Greatest Global Public Health Effort in History’ to Bridge Vaccine Gap as World Marks 4 Million Deaths from COVID-19 Pandemic
7 July 2021
SG/SM/20814
The following statement by UN Secretary-General António Guterres was issued today:

Today the world marks yet another grim milestone in the COVID-19 pandemic.  Four million souls have now been lost to the virus.  This tragic toll is more than the population of one out of three countries on earth.  Many of us know this loss directly and feel its pain.  We mourn mothers and fathers who gave guidance, sons and daughters who inspired us, grandmothers and grandfathers who shared wisdom, colleagues and friends who lifted our lives.

Vaccines offer a ray of hope — but most of the world is still in the shadows.  The virus is outpacing vaccine distribution.  This pandemic is clearly far from over; more than half its victims died this year.

Many millions more are at risk if the virus is allowed to spread like wildfire.  The more it spreads, the more variants we see — variants that are more transmissible, more deadly and more likely to undermine the effectiveness of current vaccines.

Bridging the vaccine gap requires the greatest global public health effort in history.  In short, the world needs a Global Vaccine Plan:  to at least double production of vaccines and ensure equitable distribution, using COVAX as the platform; to coordinate implementation and financing; and to support countries’ readiness and capacity to roll out immunization programmes, while tackling the serious problem of vaccine hesitancy.

 

To realize this plan, I am calling for an emergency task force that brings together all the countries with vaccine production capacities, the World Health Organization, the global vaccine alliance, GAVI, and international financial institutions able to deal with the relevant pharmaceutical companies and manufacturers, and other key stakeholders.

Vaccine equity is the greatest immediate moral test of our times.  It is also a practical necessity.  Until everyone is vaccinated, everyone is under threat.  Global recovery requires global vaccination.  The tragic loss of 4 million people to this pandemic must drive our urgent efforts to bring it to an end for everyone, everywhere.

Statement on Universal Affordable Vaccination against Coronavirus Disease covid-19, International Cooperation and Intellectual Property

Milestones :: Perspectives :: Research

 

Statement on Universal Affordable Vaccination against Coronavirus Disease covid-19, International Cooperation and Intellectual Property
United Nations – Committee on Economic, Social and Cultural Rights
Pages: 180–187
Online Publication Date: 31 May 2021
Abstract
Access to a vaccine aginst coronavirus disease (covid-19) that is safe, effective and based on the best scientific developments is an essential component of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health and the right of everyone to enjoy the benefits of scientific progress and its applications. States therefore have an obligation to take all the necessary measures, as a matter of priority and to the maximum of their available resources, to guarantee all persons access to vaccines against covid-19, without any discrimination. This statement builds on the previous statements of the Committee on Economic, Social and Cultural Rights of 6 April 2020 on the coronavirus disease (covid-19) pandemic and economic, social and cultural rights (E/C.12/2020/1) and of 27 November 2020 on universal and equitable access to vaccines for the coronavirus disease (covid-19) (E/C.12/2020/2). It is intended to remind States of their obligations under the International Covenant on Economic, Social and Cultural Rights in relation to universal access and affordability of vaccines against covid-19, particularly with regard to international cooperation and intellectual property.

A Global Deal for Our Pandemic Age

Milestones :: Perspectives :: Research

 

A Global Deal for Our Pandemic Age
Report of the G20 High Level Independent Panel on Financing the Global Commons for Pandemic Preparedness and Response
June 2021 :: 92 pages
PDF: https://pandemic-financing.org/wp-content/uploads/2021/07/G20-HLIP-Report.pdf
High Level Summary [text bolding from original]
We are in an age of pandemics. COVID-19 has painfully reminded us of what SARS, Ebola,
MERS and H1N1 had made clear, and which scientists have repeatedly warned of: without greatly
strengthened proactive strategies, global health threats will emerge more often, spread more
rapidly, take more lives, disrupt more livelihoods, and impact the world more greatly than before.

 

Together with climate change, countering the existential threat of deadly and costly
pandemics must be the human security issue of our times. There is every likelihood that
the next pandemic will come within a decade — arising from a novel influenza strain, another
coronavirus, or one of several other dangerous pathogens. Its impact on human health and the
global economy could be even more profound than that of COVID-19.

The world is nowhere near the end of the COVID-19 pandemic. Without urgent and concerted
actions and significant additional funding to accelerate global vaccination coverage, the emergence
of more variants of the virus is likely and will continue to pose a risk to every country. The solutions
for vaccinating the majority of the world’s population are available and can be implemented
within the next 12 months. More decisive political commitments and timely follow-through
will resolve this disastrous global crisis.

The world is also far from equipped to prevent or stop the next pandemic. Lessons from
COVID-19, on how the world failed to prevent the pandemic, why it has been prolonged at such
catastrophic cost, and how we can overcome the crisis if we now respond more forcefully, provide
important building blocks for the future. We must use this moment to take the bold steps needed
to avoid the next pandemic, and not allow exhaustion from current efforts to divert attention
from the very real risks ahead.

 

Plugging Four Major Gaps
Making the world safer requires stepped-up and sustained national, regional and global actions
and coordination, leveraging fully the private sector, to prevent outbreaks as well as to respond
much faster, more equitably and more effectively when a pandemic emerges.

 

We must plug four major gaps in pandemic prevention, preparedness and response:
Globally networked surveillance and research: to prevent and detect emerging infectious diseases

Resilient national systems: to strengthen a critical foundation for global pandemic preparedness
and response

Supply of medical countermeasures and tools: to radically shorten the response time to a
pandemic and deliver equitable global access

Global governance: to ensure the system is tightly coordinated, properly funded and with clear
accountability for outcomes…

Media Release
G20 High Level Independent Panel Releases Report on Financing the Global Commons for Pandemic Preparedness and Response
July 9, 2021
The National Academy of Medicine and the Wellcome Trust serve as Administrative Secretariat for a G20 High Level Executive Panel that today released a report titled A Global Deal for Our Pandemic Age. NAM President Victor J. Dzau served as advisor to the panel, whose report finds that “the world remains very poorly equipped to prevent or contain future epidemics or pandemics.” The report calls for an increase in international financing of at least $75 billion over the next five years to close gaps in pandemic prevention and preparedness, a recommendation that would at least double current spending levels. Infectious disease surveillance, resilience of national health systems, global capacity to supply and deliver vaccines and other medical countermeasures, and global governance are four areas that need the most focus, the Panel notes.

“COVID-19 has made the global nature of our health and well-being abundantly clear,” said Victor Dzau. “It is our obligation to prepare for future pandemics with a global mindset. This report makes major requests of many countries, but we know that the financial impact of a future pandemic would be much greater than the investments the Panel has identified. We must learn from COVID-19 and be ready for the next pandemic when it arrives, and that begins with appropriate funding for both prevention and preparedness.”

 

The report also identifies additional areas for international action, including:
A fundamental shift toward greater multilateral financing for global health security, including a reformed and strengthened World Health Organization;
Making global public goods, especially for pandemic security and climate action, part of the core mandate of the International Financial Institutions;
Establish a Global Health Threats Fund, mobilizing $10 billion per year in additional financing to provide strong and agile support for efforts to close gaps in global preparedness; and
Strengthen global governance for pandemic security through a new Global Health Threats Board.

Global Public Health Leaders Warn about Political Leadership that Harms

Milestones :: Perspectives :: Research

 

Global Public Health Leaders Warn about Political Leadership that Harms
WFPHA: World Federation of Public Health Associations
Jul 7, 2021
Around the world, the rapid spread of the Delta variant is posing a grave threat to pandemic control, highlighting the critical need for effective leadership informed by the best available evidence, global public health leaders have warned.

Members of the Public Health Leadership Coalition, launched earlier this year by the World Federation of Public Health Associations, met on June 28 to share updates on the COVID-19 pandemic from their respective countries.

The meeting heard that political imperatives are driving harmful policies in some countries, such as reopening and hosting big gatherings, and that the pandemic is being prolonged by global inequities in access to COVID vaccines as well as vaccine hesitancy in many countries.

“This meeting has highlighted the urgent need to make governments accountable for their choices. This is not the time for complacency, nor for a relaxed attitude,” said Prof Ricciardi, WFPHA president and coalition Chairman.

Professor K. Srinath Reddy, President of the Public Health Foundation of India, told the meeting that in India, the Delta Plus variant has recently emerged and is still being studied. The numbers of people infected by this variant are still small. “Delta variant is still the dominant virus. However, the addition of the K.417.N mutation in the Delta Plus raises concerns about reduced vaccine efficacy. This aspect is being examined,” he said.

“In Canada, the response to the pandemic has been seriously impaired by lack of political and policy alignment, and poor coordination within and across federal, provincial, and municipal levels, during all phases. This was fuelled by deficient information systems, outdated protocols and the inexperience of those in charge, and worsened by the appointment or replacement of experts with bureaucrats at key agencies,” highlighted Professor Alejandro Jadad, founder of the Centre for Global eHealth Innovation.

“In South American countries, a lack of political leadership is also contributing to the spread of COVID, especially in countries such as Colombia, Brazil and Chile,” said Professor Maria del Rocio Saenz, former Minister of Health of Costa Rica. In her own country, intensive care units were filled to capacity and the health system remains under great stress, she said. “Disadvantaged groups are more vulnerable to the variant,” she said. “The pandemic has highlighted the importance of addressing the underlying inequities in the determinants of health, such as poverty, housing, and access to healthy living conditions.”

In Africa, the third wave that started early in May is hitting hard with hospital beds capacity overwhelmed in many countries such as DRC, according to Dr Jean-Marie Okwo-Bele, former director of the Immunization and Vaccines Department at WHO. “It is vital that public health leadership helped promote evidence-informed messaging that resonates with local communities” he said.

Dr Okwo-Bele highlighted the need for political leaders, religious and other influential community leaders to urgently step up efforts to amplify critical health messages about Covid-19. “The lack of action on vaccine inequities and wider inequities is stopping recovery for everyone,” he added. “All countries and all people will benefit when global, national and local inequities are addressed.”

Delegates also raised concerns about the potential for the European Football Championships to spread COVID infections across Europe, with tens of thousands of people from all over Europe visiting London in few days. “We fear this will prove to be a seeding event for the rest of Europe,” said Professor Bettina Borisch, WFPHA CEO. “We need to advocate with organisations such UEFA and FIFA that are putting pressure on governments”.

The leadership coalition, led by Prof Walter Ricciardi, WFPHA president, is working with ministers of health from different countries and is calling on them to join forces to reduce the huge disparities in equities, regarding the supply of vaccines and beyond. Leaders stand ready to support the development and implementation of the WHO proposed Global Pandemic Treaty.

Countries must prioritise veterinarian access to COVID-19 vaccines

Milestones :: Perspectives :: Research

 

Countries must prioritise veterinarian access to COVID-19 vaccines
9 July 2021
The World Organisation for Animal Health (OIE) and the World Veterinary Association (WVA) unite in encouraging countries to prioritise COVID-19 vaccination access for veterinary professionals. Veterinarians serve the health community by working at the animal-human interface. They need priority access to vaccination services in order to pursue their work which is central to safeguarding public health.

 

Joint OIE/WVA Statement
The COVID-19 pandemic pushed the international community to reconsider how health professionals can address disease emergencies in a more coordinated way. As human health systems throughout the world have strained under ongoing pressure, veterinarians have been offering their skills and expertise to help fight against the pandemic.

This collaboration between animal and human health sectors is a great example of implementation of the One Health approach, as it recognises the need to join forces and capacities on common health objectives shared by both human and animal health sectors. While some veterinarians have supported the testing of human samplings, others have provided human health care professionals with life-saving personal protective equipment and respirators. By researching the origins of COVID-19, and conducting passive surveillance of animals, particularly those highly susceptible to SARS-CoV-2 (such as mink and other mustelids), veterinarians have also contributed to the world’s understanding of this complex virus.

In addition to their numerous contributions to the global response to COVID-19, veterinarians have strived to pursue their daily mission to ensure the health and welfare of animals, as well as public health. This multi-faceted profession has played a key role in guaranteeing the continued safety of food production chains, sufficient access to food and the security of traded animals and animal products worldwide since the start of the crisis. Despite this valuable support to the health emergency response and the economy, veterinarians have been excluded from access to priority vaccinations in some countries.

Today, the World Organisation for Animal Health (OIE) and the World Veterinary Association (WVA) call on countries to include veterinarians as priority professionals for COVID-19 vaccination within their national strategies and vaccination campaigns.

By doing so, countries ensure that their:
health emergency workforce is safe, as veterinarians have the skills and expertise to support national COVID-19 response strategies, including the administration of vaccines to humans and the testing of human samples;
food production chains are maintained, as veterinarians are critical personnel to ensure safe animal production and food safety.
national risk management strategies are well-respected, as veterinarians are in close contact with farmed animal species (such as mink and other mustelids), or with endangered species and wildlife which are highly susceptible to SARS-CoV-2. Avoiding the exposure of these animals to SARS-CoV-2 prevents the development of new animal reservoirs and future spillovers of the virus to humans. As a reminder, there is currently no evidence that companion animals, such as cats or dogs, are playing an epidemiological role in the spread of human infections of COVID-19.

Through the inclusion of veterinarians in priority vaccination access groups, countries support a coordinated One Health response to the COVID-19 crisis.  This heightened collaboration between animal and human health professionals is key to overcoming the current pandemic as well as to preventing future outbreaks.
Paris, 9 July 2021

COVID Vaccines – OCHA:: HDX

Milestones :: Perspectives :: Research

 

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
Jul 03, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

 

Global COVID-19 Figures: 185M total confirmed cases; 4.0M total confirmed deaths
Global vaccines administered: 3.36B
Number of Countries: 26 [26]
COVAX First Allocations (Number of Doses): 73M [73M]
COVAX Delivered (Number of Doses): 22M [17M]
Other Delivered (Number of Doses): 51M [49M]
Total Delivered (Number of Doses): 73M [66M]
Total Administered (Number of Doses): 61M [54M]

Coronavirus [COVID-19] – WHO Public Health Emergency of International Concern (PHEIC)

Milestones :: Perspectives :: Research

 

Coronavirus [COVID-19] – WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

 

Weekly Epidemiological and Operational updates
Last update: 2 Jul 2021
Confirmed cases :: 185 291 530 [week ago: 182 319 261]
Confirmed deaths :: 4 010 834 [week ago 3 954 324]
Vaccine doses administered: 3 078 787 056 [week ago: 2 950 104 812]

 

::::::

Director-General’s opening remarks at the media briefing on COVID-19 – 7 July 2021
7 July 2021
Variants are currently winning the race against vaccines because of inequitable vaccine production and distribution, which also threatens the global economic recovery.
I have called repeatedly for 10 percent of people in all countries to be vaccinated by September and for that figure to rise to 40 percent by the end of the year. It would position the world on the path to vaccinating 70 percent of the people in all countries by the middle of 2022.   
I call on the G20 Finance Ministers and other leaders to get behind these targets collectively because it is the fastest way to end the acute stage of the pandemic, save lives and livelihoods and drive a truly global economic recovery.
At present, IL-6 receptor blockers remain inaccessible and unaffordable for the majority of the world but it’s within the power of governments and manufacturers to change that. Going forward, it is key that the therapeutic arm of the ACT-Accelerator is fully funded so further research and development can uncover more lifesaving medicines for the prevention and treatment of COVID-19.
Tomorrow, I will join Her Majesty Queen Mathilde of the Belgians, along with UN Secretary-General Antonio Guterres, Unicef Executive Director Henrietta Fore and other leaders to discuss the impact of violence on the mental health of children. As well as looking to accelerate the end of this pandemic, giving children the support they need must be a top priority as we come out of it.
Finally, we’re shocked by the tragic news from Haiti and want to pass on our deep condolences for the passing of President of Haiti, Jovenal Moïse.  

Good morning, good afternoon and good evening.       

The world is at a perilous point in this pandemic. We have just passed the tragic milestone of 4 million recorded COVID-19 deaths, which likely underestimates the overall toll.

Some countries with high vaccination coverage are now planning to rollout booster shots in the coming months and are dropping public health social measures and relaxing as though the pandemic is already over.

However, compounded by fast moving variants and shocking inequity in vaccination, far too many countries in every region of the world are seeing sharp spikes in cases and hospitalisation.

This is leading to an acute shortage of oxygen, treatments and driving a wave of death in parts of Africa, Asia and Latin America.

 

Vaccine nationalism, where a handful of nations have taken the lion’s share, is morally indefensible and an ineffective public health strategy against a respiratory virus that is mutating quickly and becoming increasingly effective at moving from human-to-human.

At this stage in the pandemic, the fact that millions of health and care workers have still not been vaccinated is abhorrent.

Variants are currently winning the race against vaccines because of inequitable vaccine production and distribution, which also threatens the global economic recovery. It didn’t have to be this way and it doesn’t have to be this way going forward.

From a moral, epidemiological or economic point view, now is the time for the world to come together to tackle this pandemic collectively.

Later this week, G20 Finance Ministers and Central Bank Governors will meet. This is another crucial opportunity for leaders to take urgent steps to end the acute stage of this pandemic, providing the necessary funding to scale up the equitable manufacturing and distribution of health tools.

 

I have called repeatedly for 10 percent of people in all countries to be vaccinated by September and for that figure to rise to 40 percent by the end of the year. It would position the world on the path to vaccinating 70 percent of the people in all countries by the middle of 2022. 

I call on the G20 Finance Ministers and other leaders to get behind these targets collectively because it is the fastest way to end the acute stage of the pandemic, save lives and livelihoods and drive a truly global economic recovery…

 

::::::

Weekly operational update on COVID-19 – 5 July 2021
Overview
In this edition of the COVID-19 Weekly Operational Update, highlights of country-level actions and WHO support to countries include:Donating medical masks to Barbados and the Eastern Caribbean Countries
Handing over of a Control Room at COVID-19 Unified Central Hospital in Nepal
Convening a high-level meeting on post-COVID conditions in Greece
Strengthening partnerships with media in the Syrian Arab Republic to improve communication on COVID-19 vaccines
Online learning to support operationalization of a One Health Approach in countries and a new framework to support countries in strengthening health emergency preparedness
Progress on a subset of indicators from the SPRP 2021 Monitoring and Evaluation Framework
Updates on WHO’s financing to support countries in SPRP 2021 implementation and provision of critical supplies.
Weekly epidemiological update on COVID-19 – 6 July 2021
Overview
Last week, the number of new cases increased slightly, while the number of new deaths continued to decrease, with over 2.6 million new cases and just under 54 000 new deaths reported globally. This is the lowest weekly mortality figure since early October 2020. The cumulative number of cases reported globally now exceeds 183 million and the number of deaths is almost 4 million. Last week, all Regions reported an increase in new cases except for the Americas. The European Region reported a sharp increase in incidence (30%) whereas African region reported a sharp increase in mortality (23%) when compared to the previous week. All Regions, with the exception of the Americas and South-East Asia, reported an increase in the number of deaths last week.
In this edition, a special focus update on the variants is provided, which includes updates on emerging evidence surrounding the phenotypic characteristics of VOCs (transmissibility, disease severity, risk of reinfection, and impacts on diagnostics and vaccine performance), updates on the geographic distribution of VOCs and on the variant classification. It also includes the variant working definitions, as well as other variants and amino acid changes under monitoring.

::::::
::::::

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 26 June 2021
For 22 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date
[Update posted 02 July 2021; click on the link above for full scale view]

COVID Vaccine Developer/Manufacturer Announcements

Milestones :: Perspectives :: Research

 

COVID Vaccine Developer/Manufacturer Announcements [relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

 

AstraZeneca
Press Releases – No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias
Aprueba el CECMED autorizo de uso de Emergencias de Abdala
09/07/2021 15:43:46    |   BioCubaFarma

[google translate: CECMED approves authorization for the use of Abdala Emergencies]

Esquema de dos dosis de Soberana 02 con una dosis de Soberana Plus alcanza 91,2 por ciento de eficacia.
09/07/2021 01:21:46    |   BioCubaFarma

[google translate: Scheme of two doses of Soberana 02 with one dose of Soberana Plus achieves 91.2 percent efficacy.]

Umelisa SARS-COV-2 antígeno, un sistema de diagnóstico 100 % cubano
05/07/2021 12:02:41    |   Redacción de Granma

[google translate: Umelisa SARS-COV-2 antigen, a 100% Cuban diagnostic system]

 

CanSinoBIO
News – No new digest announcements identified

Clover Biopharmaceuticals – China
News
Jun 30,2021 Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover’s COVID-19 Vaccine for the COVAX Facility

Jun 30,2021 Clover and Dynavax Announce Commercial Supply Agreement of Dynavax’s CpG 1018 Adjuvant for Clover’s COVID-19 Vaccine Candidate

 

Curevac [Bayer Ag – Germany]
News
Jul 6,2021
Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements

 

Janssen/JNJ
Press Releases
Jul 09, 2021 United States
Johnson & Johnson Statement on U.S. Government Donations of Company’s COVID-19 Vaccine
NEW BRUNSWICK, N.J., July 9, 2021 – Johnson & Johnson welcomes the U.S. government’s decision to donate an initial 12 million doses of the Company’s COVID-19 vaccine through the COVAX Facility.
The United States is sharing the doses via COVAX to multiple lower-income countries across three continents. The first shipment of 1.5 million doses arrived in Afghanistan on July 9, 2021.
In the coming weeks, it is anticipated that the U.S. will allocate a second tranche of Johnson & Johnson COVID-19 vaccines to additional lower-income countries. Separately, the U.S. has already donated 8 million doses of the Company’s vaccine via a series of bilateral agreements with higher-income countries including Brazil, Colombia, Mexico and South Korea.
“Equitable global access is at the forefront of Johnson & Johnson’s COVID-19 response. We strongly support the leadership shown by the Biden-Harris Administration in ensuring lifesaving COVID-19 vaccines can be redirected to where public health needs are most pressing,” said Paul Stoffels, M.D., Chief Scientific Officer and Vice Chairman of the Executive Committee, Johnson & Johnson. “We believe that a single-shot, easy to distribute COVID-19 vaccine is an essential tool to combat the pandemic globally.”…

 

Moderna
Press Releases
July 7, 2021
Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine
:: mRNA-1010 is Moderna’s first seasonal influenza vaccine candidate to enter the clinic
:: mRNA-1010 is a quadrivalent seasonal influenza vaccine candidate targeting WHO recommendations including A H1N1, H3N2 and influenza B Yamagata and Victoria lineages
:: Moderna’s vision is to develop a respiratory vaccine for the adult and elderly populations combining seasonal flu, COVID-19 variant booster and RSV

 

Novavax
Press Releases – No new digest announcements identified

 

Pfizer
Recent Press Releases – No new digest announcements identified

 

Sanofi Pasteur
Press Releases – No new digest announcements identified

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No corporate announcements identified
[Last media release still posted is dated February 15, 2021; media release of April 21, 2021 apparently removed]

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases – No new digest announcements identified

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media – No new digest announcements identified

 

SK Biosciences
Press releases – No new digest announcements identified

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Vaccines and Related Biological Products Advisory Committee
:: No meetings scheduled

 

::::::

White House [U.S.]
Briefing Room – Selected Major COVID Announcements
Press Briefing by White House COVID-19 Response Team and Public Health Officials
July 08, 2021 • Press Briefings

Press Briefing by White House COVID-19 Response Team and Public Health Officials
July 08, 2021 • Press Briefings

Remarks by President Biden Celebrating Independence Day and Independence from COVID-19
July 05, 2021 • Speeches and Remarks

 

::::::

Joint CDC and FDA Statement on Vaccine Boosters
July 08,2021
The United States is fortunate to have highly effective vaccines that are widely available for those aged 12 and up. People who are fully vaccinated are protected from severe disease and death, including from the variants currently circulating in the country such as Delta. People who are not vaccinated remain at risk. Virtually all COVID-19 hospitalizations and deaths are among those who are unvaccinated. We encourage Americans who have not yet been vaccinated to get vaccinated as soon as possible to protect themselves and their community.

Americans who have been fully vaccinated do not need a booster shot at this time. FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data – which can include data from specific pharmaceutical companies, but does not rely on those data exclusively.

We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

European Medicines Agency
News & Press Releases  
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021 (new)
PRAC, Last updated: 09/07/2021

 

News: Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis (new)
PRAC, Last updated: 09/07/2021

 

News: EMA advises against use of COVID-19 Vaccine Janssen in people with history of capillary leak syndrome (new)
PRAC, Last updated: 09/07/2021
EMA’s safety committee (PRAC) has recommended that people who have previously had capillary leak syndrome must not be vaccinated with COVID-19 Vaccine Janssen. The Committee also recommended that capillary leak syndrome should be added to the product information as a new side effect of the vaccine, together with a warning to raise awareness among healthcare professionals and patients of this risk…

 

::::::

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates
COVID-19 in children and the role of school settings in transmission – second update
Technical report
8 Jul 2021
The aim of this document is to provide an update on the knowledge surrounding the role of children in the transmission of SARS-CoV-2 and the role of schools in the COVID-19 pandemic, focusing in particular on the experience in EU/EEA countries since the beginning of the pandemic. This document also addresses transmission to and from staff in school settings, school-related mitigation measures including risk communication, testing, contact tracing, and the effectiveness and impacts of school closures. This document draws upon and updates evidence presented in the previous reports from ECDC on this topic, which were published in August 2020 and December 2020. This report does not consider educational settings related to young adults or adults, such as universities or vocational schools or any school with overnight stays, such as boarding schools.

 

::::::

::::::

https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab

European Commission
https://ec.europa.eu/commission/presscorner/home/en
Statement 10 July 2021
Statement by President von der Leyen on the EU reaching the milestone of vaccine deliveries to vaccinate 70% of EU adults
I have good news for our European citizens today…The EU has kept its word.

This week-end, we have delivered enough vaccines to Member States to be in a position to vaccinate fully at least 70% of EU adults still this month….By tomorrow, some 500 million vaccine doses will have been distributed right across the regions of the European Union…The EU delivers.

Our vaccination campaign has accelerated tremendously since the beginning of the year…Our joint approach is a success…We will only come out of this crisis together.

COVID-19 is not yet defeated…But we are prepared to deliver more vaccines, including against new variants. Now, Member States must do everything, to increase vaccinations…Only then will we be safe.

Press release 9 July 2021
Republic of Senegal and Team Europe agree to build a manufacturing plant to produce vaccines against COVID-19 and other endemic diseases
Producing COVID-19 vaccines in Africa came one step closer today after Team Europe formally agreed to support large-scale investment in vaccine production by the Institut Pasteur in Dakar, alongside other support measures.

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

UNICEF signs first COVID-19 vaccine agreement to supply African Union
The agreement will supply up to 220 million single-dose vaccines by 2022 as part of UNICEF’s broader support for the African Vaccine Acquisition Trust (AVAT) to help provide vaccines for the 55 AU Member States
NEW YORK, 8 July 2021 – UNICEF has signed an agreement with Janssen Pharmaceutica NV to supply up to 220 million doses of the J&J single-dose vaccine for all 55 Member States of the African Union (AU) by the end of 2022. Some 35 million doses are to be delivered by the end of this year.

The agreement between UNICEF and Janssen Pharmaceutica NV will help implement the Advance Purchase Commitment (APC) signed between the African Vaccine Acquisition Trust (AVAT) and Janssen in March of this year. That agreement secured an option to order another 180 million doses, bringing the maximum access up to a total of 400 million doses by the end of 2022. 

The African Union established AVAT in November 2020 to deliver COVID-19 vaccines to the African continent, with a goal of vaccinating 60 per cent of each AU country’s population. Under the plan, the African Export-Import Bank (Afreximbank) and AVAT have signed a cooperation agreement on behalf of the AU for the development of an Advance Procurement Commitment (APC) Framework to support Member State access to COVID-19 vaccines. UNICEF will procure and deliver COVID-19 vaccines on behalf of the AVAT initiative. Other partners include the Africa Centres for Disease Control and Prevention (Africa CDC) and the World Bank. While multiple vaccines are anticipated to be part of the initiative’s portfolio, Janssen’s single-dose vaccine is the first to be included.

“African countries must have affordable and equitable access to COVID-19 vaccines as soon as possible. Vaccine access has been unequal and unfair, with less than 1 per cent of the population of the African continent currently vaccinated against COVID-19. This cannot continue,” said UNICEF Executive Director Henrietta Fore. “UNICEF, with its long history of delivering vaccines all around the world, is supporting global COVID-19 vaccinations efforts through AVAT, COVAX, and other channels to maximize supply and access to vaccines.”

Drawing upon decades of experience as the largest single vaccine buyer in the world as it does annually for routine immunization, UNICEF is acting as a procurement and logistics agency on behalf of the AVAT partnership. UNICEF stands ready to facilitate the procurement, transport and delivery of vaccines as soon as they become available and AU Member States are ready to receive them. With its extensive capacity and decades of expertise in managing freight, insurance and transport of vaccines which require strict adherence to cold chain requirements, UNICEF will work with the vaccine industry, freight forwarders and transport companies to get the doses to the communities that need them.

Janssen’s COVID-19 vaccine received a WHO Emergency Use Listing (EUL) on 12 March and is relying on a global supply network to produce the vaccine. The latest site for production, Aspen Pharmacare in Gqeberha, South Africa, was approved by the WHO on 29 June. Deliveries of the vaccine are expected to begin later in the 3rd quarter of 2021, with allocations to be determined by the Africa CDC.

The agreement comes as the African continent faces the steepest surge in COVID-19 cases yet, and vaccine supply challenges have left many countries with large unvaccinated populations…

 

::::::

Full scale, interactive dashboard available at: https://africacdc.org/covid-19-vaccination/

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

Russia: Sputnik V – “the first registered COVID-19 vaccine”
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
RDIF and Morepen Laboratories announce production of the test batch of Sputnik V in India
Press release, 06.07.2021

Test batch of the Sputnik V vaccine produced in Mexico
Press release, 05.07.2021

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

 

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

22 COVID-19 vaccines enter clinical trials in China: health official
2021-07-09
BEIJING – Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said on July 8..
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.

POLIO Public Health Emergency of International Concern (PHEIC)

Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)

Polio this week as of 07 July 2021
:: In the recently concluded Paris-held Generation Equality Forum, the World Health Organization announced multiple commitments to drive change for gender equality and the empowerment of women and girls in all their diversity. One of the commitments the organisation made is to support countries to address gender-related barriers to polio vaccination, collect and analyse sex-disaggregated data to ensure girls and boys are reached equally, and to increase women’s meaningful participation and decision-making across all levels of the polio eradication programme… Read more

:: GPEI has made available the Polio Eradication Strategy 2022-2026 Stakeholder Consultation Report which provides an outline of the strategy consultation process, as well as a summary of feedback received and responses from the authors of the strategy in relation to key points raised and questions asked.

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
:: Pakistan: one WPV1 positive environmental sample
:: Afghanistan: one cVDPV2 case
:: DR Congo: one cVDPV2 case
:: Yemen: one cVDPV1 case

 

::::::

Stakeholder Consultation Report
Polio Eradication Strategy 2022–2026 :: Delivering on a promise
GPEI
Undated :: 15 pages
INTRODUCTION
Polio Eradication Strategy 2022–2026: Delivering on a promise was developed following a
comprehensive assessment of the Global Polio Eradication Initiative’s (GPEI) management
practices and structure, alongside a programme-wide evaluation of the Polio Endgame Strategy
2019–2023 to determine what actions, interventions and transformations will be needed to
achieve polio eradication.

The development of the Polio Eradication Strategy 2022–2026 began in July 2020 and was led
by a multi-partner working group comprised of external consultants and representatives from the
GPEI’s core partners: Rotary International, the World Health Organization (WHO), the U.S.
Centers for Disease Control and Prevention (CDC), the United Nations Children’s Fund
(UNICEF), the Bill & Melinda Gates Foundation, and Gavi, the Vaccine Alliance.

This consultation process was designed to achieve the following goals:
create a transparent, inclusive strategy development process;
engage a range of audiences with varying types of expertise; and
increase awareness within the global health community that a new 2022–2026 Strategy
was under development to replace the 2019-2023 Strategy and prepare for the Post-
Certification Strategy (PCS).

This report provides an outline of the consultation process, as well as a summary of feedback
received and responses from the authors of the strategy in relation to key points raised and
questions asked.

SUMMARY OF STAKEHOLDER FEEDBACK RECEIVED THROUGH ITERATIVE REVIEWS
Common feedback themes:
Two goals to address all poliovirus have been well-received.
Stakeholders expressed interest in strategies to help the GPEI achieve deep government and
community buy-in. They welcomed the broader focus on these issues in the updated strategy,
moving away from a strictly epidemiological focus.
Detailed solutions within each goal must provide geographical specificity, wherever possible.
A gender lens must be applied to and integrated across polio eradication activities.
A monitoring and evaluation framework will be critical for confidence in the strategy.
Stakeholders expressed interest in seeing how GPEI partners will become accountable for
progress against results. Ensuring accountability will only be possible if governments clearly
demonstrate ownership – which, in turn, is cultivated through a well-tailored approach on how
the GPEI work with governments and build capacity.
On timelines, there was broad agreement that building benchmarks and milestones into the
strategy’s timeline are more important than emphasizing a timeline for eradication. The strategy’s
timeline should be positioned as a budgeting tool for planning purposes.
On the timeline for interrupting circulating vaccine-derived poliovirus type 2(cVPDV2), the
Strategy Committee (SC) agreed to three years after last cVDPV2 isolate given the case-toinfection
ratio of cVDPV2 and agreed that the Global Commission for Certification of the
Eradication of Poliomyelitis (GCC) will later define prerequisites for cVDPV2 validation.
The strategy should address transition planning – as this is equally important for focus countries
(which should begin this journey now regardless of ongoing outbreaks) and for those countries
where polio activities are already winding down.

 

::::::
::::::

WHO/OCHA Emergencies

 

Editor’s Note:
WHO has apparently reorganized and fundamentally shifted how it judges and tracks “emergencies”. We found no announcement of descriptive information to share and present the webpage structure as encountered below. Obviously, the dates associated with some of these emergencies suggest that this is an archival platform as well as a current emergencies resource.

Health emergencies list – WHO
“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”

 

Ebola outbreak, Democratic Republic of the Congo, 2021
[Last apparent update: 3 May 2021]

Ebola outbreak outbreak, N’Zerekore, Guinea, 2021 [Last apparent update: 3 May 2021]

Coronavirus disease (COVID-19) pandemic [Last apparent update 9 July 2021; See COVID above]

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020 [Last apparent update: 1 June 2021]

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020 [Last apparent update: 3 May 2021]

Ebola outbreak, Democratic Republic of the Congo, 2018 [Last apparent update: 24 July 2018]

Yemen crisis [Last apparent update: 12 February 2021]

Syria crisis [Last apparent update: 18 June 2021]

Somalia crisis [Last apparent update: 24 March 2018]

Nigeria crisis [Last apparent update: 9 May 2018]

Ebola outbreak, Democratic Republic of the Congo, 2017 [Last apparent update: 3 May 2021]

Zika virus disease outbreak, 2015-2016 [Last apparent update: 24 Jan 2020]

Ebola outbreak: West Africa, 2014-2016 [Last apparent update: 3 May 2021]

Iraq crisis [Last apparent update: 9 Jan 2008]

South Sudan crisis [Last apparent update: 23 Sep 2020]

Avian influenza A (H7N9) virus outbreak [Last apparent update: 21 May 2021]

Middle East respiratory syndrome (MERS-CoV) outbreak [Last apparent update: 8 July 2019]

Influenza A (H1N1) virus, 2009-2010 pandemic [Last apparent update: 10 Aug 2010]

 

::::::

UN OCHA – Current Emergencies
Current Corporate Emergencies
Northern Ethiopia
Ethiopia – Tigray Region Humanitarian Update Situation Report, 9 July 2021
:: Humanitarian access within most of Tigray is significantly improving, with large areas now accessible while the flow of humanitarian supplies into the region remains blocked.
:: Humanitarian partners gradually resumed operations including food distribution, water trucking, medical supplies and farming seeds.
:: Humanitarian operations are constrained by the absence of fuel, banking services, telecommunications and electricity.
:: Additional staff, supplies, and restoration of basic services are urgently needed for the continuity of humanitarian operations.
:: The Northern Ethiopia Humanitarian Response Plan is facing a significant funding gap of $433 million until the end of the year

 

::::::
::::::

MMWR News Synopsis Friday, July 9, 2021

MMWR News Synopsis Friday, July 9, 2021
:: Outcomes Among Patients Referred to Outpatient Rehabilitation Clinics After COVID-19 Diagnosis — United States, January 2020–March 2021
:: Efficacy of Portable Air Cleaners and Masking for Reducing Indoor Exposure to Simulated Exhaled SARS-CoV-2 Aerosols — United States, 2021 (Early Release July 2, 2021)
:: Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021 (Early Release July 6, 2021)

Africa CDC [to 10 Jul 2021]

Africa CDC [to 10 Jul 2021]
http://www.africacdc.org/
News
Africa CDC and MTN accelerate fight against COVID-19 with “One More Push” campaign
Complementing the ‘Adapted Africa Joint Continental Strategy for COVID-19 Pandemic’ of the African Union
Addis Ababa, Ethiopia, 8 July 2021: The Africa Centres for Disease Control and Prevention (Africa CDC) and pan-African operator MTN Group today launched a joint campaign – “One More Push” – to encourage people across the continent to not give up in the fight against COVID-19, and to continue to wear their masks, wash their hands and practice social distancing…

China CDC http://www.chinacdc.cn/en/

China CDC http://www.chinacdc.cn/en/

National Health Commission of the People’s Republic of China [to 10 Jul 2021]
http://en.nhc.gov.cn/
News
July 10: Daily briefing on novel coronavirus cases in China
On July 9, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 26 new cases of confirmed infections

China has provided over 480m doses of COVID-19 vaccines to world
2021-07-06
BEIJING — China has provided more than 480 million doses of COVID-19 vaccines to the world, a Chinese Foreign Ministry spokesperson said in Beijing on July 2.
Wang Wenbin said China is a firm believer in making COVID-19 vaccines a public good, and has provided the most vaccines to the world.
He said China so far has provided vaccines to nearly 100 countries, and announced that it has pledged to provide the first batch of 10 million doses of vaccines to COVAX.

National Medical Products Administration – PRC [to 10 Jul 2021]
http://english.nmpa.gov.cn/news.html
News
Over 1.34b doses of COVID-19 vaccines administered in China
2021-07-09
More than 1.34 billion doses of COVID-19 vaccines had been administered in China as of Wednesday, the National Health Commission announced on July 8.

22 COVID-19 vaccines enter clinical trials in China: health official
2021-07-09
BEIJING – Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said on July 8..
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.

CCDC Weekly – Weekly Reports: Current Volume (3)
2021-07-09 / No. 28
PDF of this issue
:: Foreword: The Uncertainties of Population Research: Challenges and Opportunities
:: Preplanned Studies: Trends and Challenges for Population and Health During Population Aging — China, 2015–2050
::Preplanned Studies: Trend and Factors of Population Fertility Changes From the Perspective of Economics and Education — China, 1949–2020
:: Commentary: Major Trends in Population Growth Around the World

Organization Announcements

Organization Announcements
Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

 

Paul G. Allen Frontiers Group [to 10 Jul 2021]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
News
No new digest content identified.

 

BARDA – U.S. Department of HHS [to 10 Jul 2021]
https://www.phe.gov/about/barda/Pages/default.aspx
News
No new digest content identified.

 

BMGF – Gates Foundation [to 10 Jul 2021]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
Press release
Jul 07, 2021
Bill & Melinda Gates Foundation CEO Mark Suzman Announces Initial Plans to Evolve Governance as Bill Gates and Melinda French Gates Commit $15 Billion in New Resources to Deepen and Accelerate the Foundation’s Efforts to Address Inequity
Changes will expand the number of trustees to add diversity of perspectives, strengthen governance, and ensure the foundation is positioned to enhance its impact for years to come

 

Bill & Melinda Gates Medical Research Institute [to 10 Jul 2021]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

 

CARB-X [to 10 Jul 2021]
https://carb-x.org/
News
No new digest content identified.

 

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 10 Jul 2021]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions and posting of all segments of Vaccines and Global Health: The Week in Review are available here.
:: [NEW] Informed Consent: A Monthly Review – July 2021 is now posted here

 

CEPI – Coalition for Epidemic Preparedness Innovations [to 10 Jul 2021]
http://cepi.net/
Latest News
CEPI to fund study of COVID-19 vaccine efficacy in immunosuppressed and transplant patients, led by Oslo University Hospital
July 6, 2021; Oslo, Norway: The Coalition for Epidemic Preparedness Innovations (CEPI) today announced that it will co-fund a study to assess the immune response to COVID-19 vaccination in patients aged 18 years or older who are immunosuppressed or who have received an organ transplant and are receiving immunosuppressive medication. CEPI will provide US$3.1 million (NOK26 million) in funding for this trial. An additional $3.6 million (NOK30 million) is provided by a consortium of leading Norwegian health organisations including the Norwegian Institute of Public Health, Diakonhjemmet Hospital, Akershus University Hospital, Haukeland University Hospital, Sørlandet Hospital Trust, Oslo University Hospital, and the Institute of Clinical Medicine at the University of Oslo. Oslo University Hospital will lead the study.

 

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 10 Jul 2021]
https://cioms.ch/
News; Publications
No new digest content identified.

 

DARPA – Defense Advanced Research Projects Agency [to 10 Jul 2021
https://www.darpa.mil/news
News
No new digest content identified.

 

Duke Global Health Innovation Center [to 10 Jul 2021]
https://dukeghic.org/
No new digest content identified.

 

EDCTP [to 10 Jul 2021]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

 

Emory Vaccine Center [to 10 Jul 2021]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

 

European Vaccine Initiative [to 10 Jul 2021]
http://www.euvaccine.eu/
Latest News
No new digest content identified

 

FDA [to 10 Jul 2021]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
July 9, 2021 – Coronavirus (COVID-19) Update: July 9, 2021

July 8, 2021 – Joint CDC and FDA Statement on Vaccine Boosters
[See COVID USA above for detail]

July 6, 2021 – Coronavirus (COVID-19) Update: July 6, 2021
:: On Thursday, June 29, 2021, Acting FDA Commissioner Janet Woodcock, M.D. and the Director of FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D., Ph.D., discussed the updates on myocarditis and pericarditis following vaccination with the Pfizer-BioNTech or Moderna COVID-19 Vaccines during a stakeholder call with Vaccinate Your Family and pediatric and healthcare groups. To watch and listen to the call, visit FDA’s YouTube channelExternal Link Disclaimer.

 

Fondation Merieux [to 10 Jul 2021]
http://www.fondation-merieux.org/
News, Events
No new digest content identified

 

Gavi [to 10 Jul 2021]
https://www.gavi.org/
News Releases
No new digest content identified.

 

GHIT Fund [to 10 Jul 2021]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 212 with the aim of developing new tools to tackle infectious diseases that
No new digest content identified.

 

Global Fund [to 10 Jul 2021]
https://www.theglobalfund.org/en/news/
News & Stories
No new digest content identified.

 

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 10 Jul 2021]
https://www.glopid-r.org/news/
News
Where to next? Crucial insights on trends and gaps for future research funding in the long battle against COVID-19
05/07/2021
Researchers and funders around the world can tap into the latest trends and gaps for future COVID-19 research to funnel resources towards greatest research needs.
…The UKCDR/GloPID-R COVID-19 Research Project Tracker continues to be one of the most comprehensive resources on COVID-19 research funding globally. It now contains over 11,397 funded research projects from more than 227 different research funders in 142 different countries, representing an investment of at least $4.8 billion (as of 2 July 2021)…

 

Hilleman Laboratories [to 10 Jul 2021]
http://www.hillemanlabs.org/
Website reports “under maintenance” at inquiry

 

Human Vaccines Project [to 10 Jul 2021]
http://www.humanvaccinesproject.org/
News
News webpage not responding at inquiry

 

IAVI [to 10 Jul 2021]
https://www.iavi.org/newsroom
Latest News
No new digest content identified.

 

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

 

ICRC [to 10 Jul 2021]
https://www.icrc.org/en/whats-new
Selected News Releases, Statements, Reports
The World Bank, ICRC and UNICEF launch a report on joining forces in humanitarian and development collaboration to improve responses to protracted crises
Water and sanitation are priorities in both humanitarian and development work, but evidence shows that a lack of collaboration in conflict and violence-affected contexts between humanitarian and development support agencies is increasing costs, reduc
09-07-2021 | News release

Bangladesh: ICRC donates body bags, PPE items to ensure dignified handling of COVID-19 deceased
To ensure the safety of those who handle the bodies, the ICRC donated 2,535 body bags and 73,293 items of Personal Protective Equipment (PPE) to different agencies of first responders across Bangladesh.
05-07-2021 | Article

 

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
Global regulators and coalition of pharma and vaccine manufacturing associations come together to discuss COVID-19 pandemic response (July 2021)
[See COVID above for detail]

 

 

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

 

IFRC [to 10 Jul 2021]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Global
IFRC warns human-caused climate change made record-breaking heatwave 150 times more likely, putting lives at risk
Geneva, 8 July 2021 – Recent rocketing temperatures are having a severe impact on millions of people and putting lives at risk, the International Federation of Red Cross and Red Crescent Societies (IFRC) has warned. Last week’s record-breaking heatwave …
8 July 2021

Bangladesh
Bangladesh: Delta fuels deadly COVID-19 surge amid crippling vaccine shortfalls
Kuala Lumpur/Dhaka/Geneva, 06 July 2021: Urgent action is needed to increase COVID-19 vaccine supplies for Bangladesh as hospitals reach capacity and oxygen supplies run short across the country.  The deadly Delta COVID-19 variant is spreading fast in …
6 July 2021

 

Institut Pasteur [to 10 Jul 2021]
https://www.pasteur.fr/en/press-area
Press Documents
No new digest content identified.

 

IOM / International Organization for Migration [to 10 Jul 2021]
http://www.iom.int/press-room/press-releases
News
IOM Launches Open South America Portal
2021-07-09 17:48
Buenos Aires – IOM, the International Organization for Migration, this week launched the Open South America Portal, a web platform providing migrants and stakeholders in the region with access to reliable and timely information on…

 

IVAC [to 10 Jul 2021]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

 

IVI [to 10 Jul 2021]
http://www.ivi.int/
Selected IVI News, Announcements, Events
IVI and KNUST establish collaborating center to conduct vaccine research and development for global health
July 5, 2021 – SEOUL, Republic of Korea and KUMASI, Ghana – The International Vaccine Institute (IVI) and the Kwame Nkrumah University of Science and Technology (KNUST) opened the KNUST-IVI Collaborating Center today with a ceremony at KNUST/Agogo Presbyterian Hospital.
The KNUST-IVI Collaborating Center will be a research and training site to implement ongoing and new collaborative projects, including disease surveillance, vaccine clinical development, vaccination campaigns, and vaccine effectiveness and health economics studies for infectious diseases prevalent to the region such as typhoid and invasive non-typhoidal Salmonella. The KNUST-IVI Collaborating Center is the first of its kind, initiated by IVI to enable joint research, development, and capacity-building activities to achieve regional health objectives as well as the UN’s global goals…

 

JEE Alliance [to 10 Jul 2021]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 

Johns Hopkins Center for Health Security [to 10 Jul 2021]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
No new digest content identified.

 

MSF/Médecins Sans Frontières [to 10 Jul 2021]
http://www.msf.org/
Latest [Selected Announcements]
Madagascar
Food assistance urgently needed as nutrition crisis grips southern Madagascar
Project Update 9 Jul 2021

Syria
Millions of Syrians will lose access to vital aid if northwest border closes
Project Update 8 Jul 2021

Ethiopia
MSF calls for Tigray murders investigation and safety for humanitarian workers
Press Release 7 Jul 2021

In Memoriam
María, Yohannes and Tedros, remembered by their colleagues
Voices from the Field 7 Jul 2021

Mediterranean migration
MSF is determined to return to sea to save lives after Geo Barents detained in Italy
Press Release 4 Jul 2021

 

National Academy of Medicine – USA [to 10 Jul 2021]
https://nam.edu/programs/
Selected News/Programs
G20 High Level Independent Panel Releases Report on Financing the Global Commons for Pandemic Preparedness and Response
July 9, 2021
[See COVID above for detail]

 

National Vaccine Program Office – U.S. HHS [to 10 Jul 2021]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

 

NIH [to 10 Jul 2021]
http://www.nih.gov/news-events/news-releases
News Releases
NIH study associates COVID-19 surges with mortality increases for patients
July 8, 2021 — The analysis looked at data from 150,000 COVID-19 inpatients from 558 U.S. hospitals from March to August of 2020.

IH COVID-19 testing initiative funds additional research projects to safely return children to in-person school
July 2, 2021 — The awards are the second installment of the Safe Return to School Diagnostic Testing Initiative.

 

PATH [to 10 Jul 2021]
https://www.path.org/media-center/
Press Releases
PATH welcomes Dr. Lutz Hegemann to the board of directors
July 7, 2021 – PATH’s board of directors is pleased to welcome Dr. Lutz Hegemann as its newest member. Dr. Hegemann will bring a unique mix of private-sector, research, and medical experience to the board.
“As we embark on the new PATH Strategy 2025, the board has a critical role in overseeing its implementation and supporting the global team in shaping the future of this organization,” said David King, chair of PATH’s board of directors. “We are fortunate to have Dr. Lutz join us at this pivotal moment. His expertise, experience, and perspective will be invaluable for PATH in the years ahead.”
Dr. Lutz Hegemann currently serves as the Group Head of Corporate Affairs and Global Health at Novartis International, where he is responsible for driving forward the corporate strategy of Novartis and integrating global health and environmental, social, and governance matters into the core of the business. He previously held the position of Chief Operating Officer for Global Health at Novartis. Dr. Hegemann has worked at Novartis since 2005 in roles of increasing responsibility…

 

Sabin Vaccine Institute [to 10 Jul 2021]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

 

UNAIDS [to 10 Jul 2021]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
8 July 2021
UNDP and UNAIDS support more than 300 pregnant and breastfeeding women living with HIV in Abidjan

8 July 2021
African first lady technical advisers align OAFLAD’s strategic plan with the new HIV targets

6 July 2021
UNAIDS saddened by the death of Phumzile Mabizela

5 July 2021
YouTube influencers campaign to increase PrEP uptake among Mandarin-speaking people in Australia

5 July 2021
Ending AIDS on wheels: a drive with Samuel Larkai

 

UNHCR Office of the United Nations High Commissioner for Refugees [to 10 Jul 2021]
http://www.unhcr.org/en-us/media-centre.htmlS
Selected News Releases, Announcements
Data visualization brings to light COVID-19’s threats to forcibly displaced women and children
5 Jul 2021

 

UNICEF [to 10 Jul 2021]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Press release
07/09/2021
1.4 million doses of COVID-19 vaccine arrive in Afghanistan through COVAX global dose-sharing mechanism
KABUL, 9 July 2021 – More than 1.4 million doses of the Johnson & Johnson COVID-19 vaccine arrived today in Afghanistan. Donated by the United States to COVAX, the 1,484,900 doses were delivered through the COVAX Facility’s dose-sharing scheme to the Government of Afghanistan.
This is the first of two vaccine consignments to arrive this month, bringing the total donation to around 3.3 million doses…

Press release
07/08/2021
UNICEF signs first COVID-19 vaccine agreement to supply African Union
The agreement will supply up to 220 million single-dose vaccines by 2022 as part of UNICEF’s broader support for the African Vaccine Acquisition Trust (AVAT) to help provide vaccines for the 55 AU Member States
[See COVID above for detail]

 

Unitaid [to 10 Jul 2021]
https://unitaid.org/
Featured News
Unitaid statement on WHO recommendations for tocilizumab and sarilumab
Geneva, 7 July 2021 – Unitaid welcomes new recommendations released by the World Health Organisation for the clinical care package for patients with severe or critical COVID-19, adding two medicines (tocilizumab and sarilumab). Having more treatment options is clearly of huge benefit, especially given the current concerning epidemiological situation around the world.
Equitable access arrangements for medicines to treat patients with advanced COVID-19, and those for earlier stages of the disease, are key to fighting the pandemic. Access to COVID-19 (ACT) Accelerator partners are ready to support effective new therapeutic products for COVID-19, and we would welcome further details from Roche and Sanofi, respectively, on their plans for broad, sustainable access to these medicines to treat COVID-19 in low- and middle-income countries.
In addition, these newly recommended medicines need to be used together with oxygen and corticosteroids, underlining the urgent need to increase access to medical oxygen and ensure adequate supplies of corticosteroids. The ACT-A Therapeutics pillar is already working to address this, with an advance purchase in 2020 of nearly 3 million doses of dexamethasone, and more recently the coordination of the COVID-19 Oxygen Emergency Taskforce.

Vaccine Equity Initiative [to 10 Jul 2021]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

 

Vaccination Acceptance & Demand Initiative [Sabin) [to 10 Jul 2021]
https://www.vaccineacceptance.org/
Announcements
No new digest content identified.

 

Vaccine Confidence Project [to 10 Jul 2021]
http://www.vaccineconfidence.org/
News, Research and Reports
Coronavirus global impact
Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 10 Jul 2021]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

 

Wellcome Trust [to 10 Jul 2021]
https://wellcome.ac.uk/news
News and reports
Opinion
Author – Beth Thompson
To avoid the next pandemic we must invest in global solutions
9 July 2021

 

The Wistar Institute [to 10 Jul 2021]
https://www.wistar.org/news/press-releases
Press Releases
No new digest content identified.

 

WFPHA: World Federation of Public Health Associations [to 10 Jul 2021]
https://www.wfpha.org/
Latest News
Global Public Health Leaders Warn about Political Leadership that Harms
Jul 7, 2021
[See COVID above for detail]

 

World Bank [to 10 Jul 2021]
http://www.worldbank.org/en/news/all
Selected News, Announcements
Responding to COVID-19 Across the Horn of Africa
In the Horn of Africa, conflicts and famine have triggered the displacement of millions of people within countries and across borders. Today, there are more than 2.7 million refugees and over six million…
Date: July 07, 2021 Type: Feature Story

Sri Lanka Gets First Batch of World Bank-financed COVID-19 Vaccines
COLOMBO, July 5, 2021—A consignment of Pfizer vaccines today arrived in Colombo, the first batch of 800,000 doses to be delivered in the next few weeks. A total of five million vaccines financed through…
Date: July 05, 2021 Type: Press Release

 

World Customs Organization – WCO [to 10 Jul 2021]
http://www.wcoomd.org/
Latest News – Selected Items
No new digest content identified.

 

World Organisation for Animal Health (OIE) [to 10 Jul 2021]
https://www.oie.int/en/for-the-media/press-releases/2021/
Press Releases, Statements
Statements
Countries must prioritise veterinarian access to COVID-19 vaccines
9 July 2021
[See COVID above for detail]

Expert’s voice
Supporting countries to better prepare and respond to zoonotic diseases: reflection from the Tripartite
6 July 2021
Technical officers from the Tripartite Organizations: the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and the World Health Organization (WHO), discuss zoonotic diseases (those that can pass between humans and animals) and how to support countries with their disease control and prevention interventions…

 

WTO – World Trade Organisation [to 10 Jul 2021]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events
DG Okonjo-Iweala highlights vital role of trade for global food security
6 July 2021
Addressing the Global Dialogue on Trade, a 6 July event organized by the WTO Secretariat in collaboration with the United Nations Food Systems Summit, Director-General Ngozi Okonjo-Iweala underlined the growing importance of international trade in building the food systems needed for the 21st century.

 

 

::::::

 

ARM [Alliance for Regenerative Medicine] [to 10 Jul 2021]
Press Releases – Alliance for Regenerative Medicine (alliancerm.org)
Selected Press Releases
No new digest content identified.

 

BIO [to 10 Jul 2021]
https://www.bio.org/press-releases
Press Releases, Letters, Testimony, Comments [Selected]
No new digest content identified.

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 10 Jul 2021]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

 

ICBA – International Council of Biotechnology Associations [to 10 Jul 2021]
https://internationalbiotech.org/news/
News
No new digest content identified.

 

IFPMA [to 10 Jul 2021]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
Global regulators and coalition of pharma and vaccine manufacturing associations come together to discuss COVID-19
06 July 2021
On 7 July 2021, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a (virtual) workshop titled ‘Enabling Manufacturing Capacity in the COVID-19 Pandemic’ [link] with representatives from the leading association bodies representing biotech firms, developing and industrialized countries vaccine manufacturers, as well as innovative biopharmaceutical, generic and biosimilar companies.
This first workshop with ICMRA members is an opportunity for the biopharmaceutical and vaccines industry to discuss and harmonize the regulatory strategies, approaches and tools that can enable pharmaceutical product manufacturers to increase manufacturing capacity even more rapidly for the production of COVID-19 vaccines and therapeutics to meet global demand. It will also focus on the considerable ongoing efforts already underway since the beginning of the coronavirus pandemic to avoid or mitigate shortages of vaccines and therapeutics for non-COVID-19-related products…

 

International Alliance of Patients’ Organizations – IAPO [to 10 Jul 2021]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

 

PhRMA [to 10 Jul 2021]
http://www.phrma.org/
Latest News [Selected]
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
July 2, 2021
The successful development and distribution of the COVID-19 vaccines have given newfound hope in the U.S. that the pandemic may be waning.
Blog Post

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org